文献速递肝病

α1-抗胰蛋白酶Pi*Z变异杂合携带增加肝硬化风险

Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis.
PubMed 文献 · Gut · 2018-08-01

该多中心病例对照研究分析了1184例经活检证实的非酒精性脂肪性肝病(NAFLD)患者和2462例慢性酒精滥用者,发现Pi*Z变异在肝硬化NAFLD患者中占13.8%,而无肝纤维化者仅占2.4%(p<0.0001),调整OR=7.3(95%CI 2.2至24.8);在酒精滥用者中,肝硬化者Pi*Z占6.2%,无显著肝损伤者占2.2%(p<0.0001),调整OR=5.8(95%CI 2.9至11.7)。Pi*S变异与NAFLD相关肝硬化无关,与酒精相关肝硬化仅边缘相关(调整OR=1.47,95%CI 0.99至2.19)。

要点

  • Pi*Z变异在肝硬化NAFLD患者中占13.8%,无肝纤维化者占2.4%(p<0.0001)。
  • 酒精滥用者中,肝硬化者Pi*Z占6.2%,无显著肝损伤者占2.2%(p<0.0001)。
  • Pi*S变异与NAFLD相关肝硬化无关,与酒精相关肝硬化仅边缘相关。

核心结论

  • Pi*Z变异是NAFLD和酒精滥用人群中迄今最强的基于单核苷酸多态性的肝硬化风险因素。
  • Pi*S变异在酒精滥用者中仅 confer 弱风险。
  • 鉴于2%-4%的白种人为Pi*Z携带者,该发现应纳入相关个体的遗传咨询。

研究设计与样本

  • 多中心病例对照研究,纳入1184例经活检证实的NAFLD患者和2462例慢性酒精滥用者,两队列均包含肝硬化病例和无肝硬化对照。
  • 对Pi*Z和Pi*S变异进行基因分型。

主要发现

  • Pi*Z变异在肝硬化NAFLD患者中占13.8%,而无肝纤维化对照仅占2.4%(p<0.0001)。
  • Pi*Z变异增加NAFLD患者发生肝硬化的风险,调整OR=7.3(95%CI 2.2至24.8)。
  • Pi*Z变异在肝硬化酒精滥用者中占6.2%,而无显著肝损伤的酒精滥用者中占2.2%(p<0.0001)。
  • 携带Pi*Z变异的酒精滥用者易发生肝硬化,调整OR=5.8(95%CI 2.9至11.7)。
  • Pi*S变异与NAFLD相关肝硬化无关,与酒精相关肝硬化仅边缘相关(调整OR=1.47,95%CI 0.99至2.19)。

关键数值与推荐

  • NAFLD队列中,肝硬化患者Pi*Z携带率为13.8%,无肝纤维化者为2.4%(p<0.0001)。
  • 酒精滥用队列中,肝硬化患者Pi*Z携带率为6.2%,无显著肝损伤者为2.2%(p<0.0001)。
  • NAFLD患者中Pi*Z变异与肝硬化的调整OR=7.3(95%CI 2.2至24.8)。
  • 酒精滥用者中Pi*Z变异与肝硬化的调整OR=5.8(95%CI 2.9至11.7)。
  • Pi*S变异与酒精相关肝硬化的调整OR=1.47(95%CI 0.99至2.19)。

临床怎么用

  • 原文结论指出,鉴于2%-4%的白种人为Pi*Z携带者,该发现应纳入相关个体的遗传咨询。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Homozygous alpha1-antitrypsin (AAT) deficiency increases the risk for developing cirrhosis, whereas the relevance of heterozygous carriage remains unclear. Hence, we evaluated the impact of the two most relevant AAT variants ('Pi*Z' and 'Pi*S'), present in up to 10% of Caucasians, on subjects with non-alcoholic fatty liver disease (NAFLD) or alcohol misuse. DESIGN: We analysed multicentric case-control cohorts consisting of 1184 people with biopsy-proven NAFLD and of 2462 people with chronic alcohol misuse, both cohorts comprising cases with cirrhosis and controls without cirrhosis. Genotyping for the Pi*Z and Pi*S variants was performed. RESULTS: The Pi*Z variant presented in 13.8% of patients with cirrhotic NAFLD but only in 2.4% of counterparts without liver fibrosis (p<0.0001). Accordingly, the Pi*Z variant increased the risk of NAFLD subjects to develop cirrhosis (adjusted OR=7.3 (95% CI 2.2 to 24.8)). Likewise, the Pi*Z variant presented in 6.2% of alcohol misusers with cirrhosis but only in 2.2% of alcohol misusers without significant liver injury (p<0.0001). Correspondingly, alcohol misusers carrying the Pi*Z variant were prone to develop cirrhosis (adjusted OR=5.8 (95% CI 2.9 to 11.7)). In contrast, the Pi*S variant was not associated with NAFLD-related cirrhosis and only borderline with alcohol-related cirrhosis (adjusted OR=1.47 (95% CI 0.99 to 2.19)). CONCLUSION: The Pi*Z variant is the hitherto strongest single nucleotide polymorphism-based risk factor for cirrhosis in NAFLD and alcohol misuse, whereas the Pi*S variant confers only a weak risk in alcohol misusers. As 2%-4% of Caucasians are Pi*Z carriers, this finding should be considered in genetic counselling of affected individuals.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Strnad P, Buch S, Hamesch K, et al. Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. Gut. 2018. PMID: 30068662. doi:10.1136/gutjnl-2018-316228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。